	US 12,331,077 B2
	Stabilized pre-fusion RSV F proteins
Johannes Petrus Maria Langedijk, Amsterdam (NL)
Assigned to Janssen Vaccines & Prevention B.V., Leiden (NL)
Appl. No. 17/293,364
Filed by JANSSEN VACCINES & PREVENTION B.V., Leiden (NL)
PCT Filed Nov. 12, 2019, PCT No. PCT/EP2019/080989 § 371(c)(1), (2) Date May 12, 2021, PCT Pub. No. WO2020/099383, PCT Pub. Date May 22, 2020.
Claims priority of application No. 18205863 (EP), filed on Nov. 13, 2018.
Prior Publication US 2022/0017574 A1, Jan. 20, 2022
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); C07K 2319/735 (2013.01); C12N 2760/18522 (2013.01); C12N 2760/18534 (2013.01)]

17 Claims

1. A recombinant pre-fusion respiratory syncytial virus (RSV) Fusion (F) protein comprising stabilizing amino acid mutations on positions 101, 152, and 486, wherein the amino acid on position 101 is Q, the amino acid on position 152 is M, and the amino acid on position 486 is N, and wherein the stabilizing amino acid mutations on the indicated positions increase the stability of the protein in the pre-fusion conformation, and wherein the amino acid positions of the F protein are to be numbered with reference to the numbering of the F protein of SEQ ID NO: 13 (for subgroup A) or SEQ ID NO: 14 (for subgroup B).